Summary by Futu AI
Intelligent Bio Solutions announced positive results from its Pharmacokinetic study, a crucial milestone for FDA 510(k) submission. The study successfully demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, showing quantitative data closely aligned to blood at 95% confidence level. The study involved 39 diverse subjects and compared opiate levels in fingerprint sweat with blood, oral fluid, and urine samples.The company's Intelligent Fingerprinting Drug Screening System enables rapid drug detection through fingerprint sweat analysis, with results available in under 10 minutes. The system screens for common workplace drugs including opiates, cocaine, methamphetamine, and cannabis. All specimens were analyzed using validated LC-MS/MS methodology.Upon receiving FDA 510(k) clearance, expected after submission in Q4 2024, INBS plans to launch its technology in the US market in 2025. The company aims to serve safety-critical industries including construction, mining, transportation, as well as law enforcement and drug rehabilitation sectors.